Symbols / TERN
TERN Chart
About
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 4.51B |
| Enterprise Value | 3.44B | Income | -94.44M | Sales | — |
| Book/sh | 3.25 | Cash/sh | 3.28 | Dividend Yield | — |
| Payout | 0.00% | Employees | 59 | IPO | — |
| P/E | — | Forward P/E | -33.43 | PEG | — |
| P/S | — | P/B | 12.77 | P/C | — |
| EV/EBITDA | -31.75 | EV/Sales | — | Quick Ratio | 19.21 |
| Current Ratio | 19.52 | Debt/Eq | 0.36 | LT Debt/Eq | — |
| EPS (ttm) | -1.02 | EPS next Y | -1.24 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-19 | ROA | -19.94% |
| ROE | -29.12% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 108.77M |
| Shs Float | 85.20M | Short Float | 15.86% | Short Ratio | 7.89 |
| Short Interest | — | 52W High | 48.26 | 52W Low | 1.86 |
| Beta | -0.28 | Avg Volume | 3.03M | Volume | 1.26M |
| Target Price | $58.11 | Recom | Strong_buy | Prev Close | $40.86 |
| Price | $41.45 | Change | 1.44% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$58.11
Mean price target
2. Current target
$41.45
Latest analyst target
3. DCF / Fair value
$-8.48
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$41.45
Low
$54.00
High
$70.00
Mean
$58.11
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-11 | main | Citizens | Market Outperform → Market Outperform | $57 |
| 2025-12-09 | main | Truist Securities | Buy → Buy | $56 |
| 2025-12-09 | main | Oppenheimer | Outperform → Outperform | $58 |
| 2025-12-09 | main | BMO Capital | Outperform → Outperform | $54 |
| 2025-12-09 | main | Barclays | Overweight → Overweight | $56 |
| 2025-12-09 | main | Mizuho | Outperform → Outperform | $54 |
| 2025-12-09 | main | HC Wainwright & Co. | Buy → Buy | $60 |
| 2025-11-26 | main | Citizens | Market Outperform → Market Outperform | $35 |
| 2025-11-25 | main | Barclays | Overweight → Overweight | $36 |
| 2025-11-19 | main | Truist Securities | Buy → Buy | $35 |
| 2025-11-18 | main | BMO Capital | Outperform → Outperform | $30 |
| 2025-11-13 | main | Mizuho | Outperform → Outperform | $33 |
| 2025-11-11 | main | Barclays | Overweight → Overweight | $28 |
| 2025-11-04 | reit | Truist Securities | Buy → Buy | $28 |
| 2025-11-04 | main | BMO Capital | Outperform → Outperform | $22 |
| 2025-11-04 | main | Barclays | Overweight → Overweight | $27 |
| 2025-11-04 | up | HC Wainwright & Co. | Neutral → Buy | $20 |
| 2025-11-04 | main | Mizuho | Outperform → Outperform | $32 |
| 2025-11-03 | up | William Blair | Market Perform → Outperform | — |
| 2025-11-03 | main | Jefferies | Buy → Buy | $35 |
- Commit To Buy Terns Pharmaceuticals At $30, Earn 34% Using Options - Nasdaq Mon, 23 Feb 2026 17
- Terns Pharmaceuticals (TERN) Climbs 53% on Stellar Leukemia Treatment Trial - Yahoo Finance Sun, 14 Dec 2025 08
- Fund Update: New $76.5M $TERN stock position opened by AMERIPRISE FINANCIAL INC - Quiver Quantitative ue, 17 Feb 2026 18
- (TERN) Risk Channels and Responsive Allocation - Stock Traders Daily Sat, 21 Feb 2026 18
- Reaffirming Buy on Terns Pharmaceuticals: Strong Early TERN-701 Data Drive Upgraded Long-Term Revenue Outlook and Upside Potential - TipRanks hu, 19 Feb 2026 12
- Terns Pharma (NASDAQ: TERN) TERN-701 Achieves 75% MMR; ASH Oral Presentation - Stock Titan Mon, 03 Nov 2025 08
- Terns Pharmaceuticals: CML Data Blows Wall Street Away - Again (NASDAQ:TERN) - Seeking Alpha ue, 09 Dec 2025 08
- Terns Pharmaceuticals stock soars on promising data for CML therapy - Investing.com Mon, 03 Nov 2025 08
- Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors - The Motley Fool Wed, 03 Dec 2025 08
- Terns Pharmaceuticals (TERN) Is Up 6.8% After Leerink Highlights TERN-701’s Early ‘Best-in-Class’ Potential – Has The Bull Case Changed? - simplywall.st hu, 12 Feb 2026 08
- Why Terns Pharmaceuticals (TERN) Is Up 54.9% After Upsized $650 Million Equity Raise Following TERN-701 Data - Yahoo Finance Wed, 10 Dec 2025 08
- $TERN stock is up 13% today. Here's what we see in our data. - Quiver Quantitative Mon, 17 Nov 2025 08
- Leerink Partners initiates Terns Pharmaceuticals stock with Outperform rating - Investing.com Mon, 09 Feb 2026 08
- Wall Street Analysts See a 50.91% Upside in Terns Pharmaceuticals (TERN): Can the Stock Really Move This High? - Yahoo Finance Wed, 04 Feb 2026 08
- Insider Sale: Chief Executive Officer of $TERN Sells 71,339 Shares | TERN Stock News - Quiver Quantitative Wed, 07 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 14583 | 571579 | — | Sale at price 38.07 - 39.80 per share. | BURROUGHS AMY LOUISE | Chief Executive Officer | — | 2026-02-17 00:00:00 | D |
| 1 | 14583 | 67665 | — | Conversion of Exercise of derivative security at price 4.64 per share. | BURROUGHS AMY LOUISE | Chief Executive Officer | — | 2026-02-17 00:00:00 | D |
| 2 | 68749 | 2548603 | — | Sale at price 37.02 - 37.53 per share. | BURROUGHS AMY LOUISE | Chief Executive Officer | — | 2026-01-15 00:00:00 | D |
| 3 | 68749 | 318995 | — | Conversion of Exercise of derivative security at price 4.64 per share. | BURROUGHS AMY LOUISE | Chief Executive Officer | — | 2026-01-15 00:00:00 | D |
| 4 | 68750 | — | — | Stock Award(Grant) at price 0.00 per share. | GENGOS ANDREW | Chief Financial Officer | — | 2026-01-14 00:00:00 | D |
| 5 | 150000 | — | — | Stock Award(Grant) at price 0.00 per share. | BURROUGHS AMY LOUISE | Chief Executive Officer | — | 2026-01-14 00:00:00 | D |
| 6 | 56250 | — | — | Stock Award(Grant) at price 0.00 per share. | KURIAKOSE EMIL T. | Officer | — | 2026-01-14 00:00:00 | D |
| 7 | 71339 | 2718230 | — | Sale at price 38.10 per share. | BURROUGHS AMY LOUISE | Chief Executive Officer | — | 2026-01-05 00:00:00 | D |
| 8 | 171551 | 99997 | — | Conversion of Exercise of derivative security at price 4.64 per share. | BURROUGHS AMY LOUISE | Chief Executive Officer | — | 2026-01-05 00:00:00 | D |
| 9 | 1155 | 44552 | — | Sale at price 38.36 - 39.60 per share. | KURIAKOSE EMIL T. | Officer | — | 2026-01-02 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | -100.97M | -101.68M | -61.00M | -49.35M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -88.85M | -90.21M | -60.34M | -50.16M |
| ReconciledDepreciation | 896.00K | 881.00K | 1.03M | 512.00K |
| EBITDA | -100.97M | -101.68M | -61.00M | -49.35M |
| EBIT | -101.87M | -102.56M | -62.03M | -49.86M |
| NetInterestIncome | 13.29M | 12.90M | 2.11M | 170.00K |
| InterestIncome | 13.29M | 12.90M | 2.11M | 170.00K |
| NormalizedIncome | -88.85M | -90.21M | -60.34M | -50.16M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -88.85M | -90.21M | -60.34M | -50.16M |
| TotalExpenses | 101.87M | 102.56M | 62.03M | 50.86M |
| TotalOperatingIncomeAsReported | -101.87M | -102.56M | -62.03M | -49.86M |
| DilutedAverageShares | 79.51M | 71.26M | 36.03M | 22.71M |
| BasicAverageShares | 79.51M | 71.26M | 36.03M | 22.71M |
| DilutedEPS | -1.12 | -1.27 | -1.67 | -2.21 |
| BasicEPS | -1.12 | -1.27 | -1.67 | -2.21 |
| DilutedNIAvailtoComStockholders | -88.85M | -90.21M | -60.34M | -50.16M |
| NetIncomeCommonStockholders | -88.85M | -90.21M | -60.34M | -50.16M |
| OtherunderPreferredStockDividend | 0.00 | |||
| NetIncome | -88.85M | -90.21M | -60.34M | -50.16M |
| MinorityInterests | 0.00 | |||
| NetIncomeIncludingNoncontrollingInterests | -88.85M | -90.21M | -60.34M | -50.16M |
| NetIncomeContinuousOperations | -88.85M | -90.21M | -60.34M | -50.16M |
| TaxProvision | 260.00K | 239.00K | 358.00K | 508.00K |
| PretaxIncome | -88.59M | -89.97M | -59.99M | -49.65M |
| OtherIncomeExpense | -11.00K | -314.00K | -68.00K | 40.00K |
| OtherNonOperatingIncomeExpenses | -11.00K | -314.00K | -68.00K | 40.00K |
| NetNonOperatingInterestIncomeExpense | 13.29M | 12.90M | 2.11M | 170.00K |
| InterestIncomeNonOperating | 13.29M | 12.90M | 2.11M | 170.00K |
| OperatingIncome | -101.87M | -102.56M | -62.03M | -49.86M |
| OperatingExpense | 101.87M | 102.56M | 62.03M | 50.86M |
| ResearchAndDevelopment | 70.11M | 63.50M | 39.62M | 31.31M |
| SellingGeneralAndAdministration | 31.76M | 39.06M | 22.41M | 19.55M |
| GeneralAndAdministrativeExpense | 31.76M | 39.06M | 22.41M | 19.55M |
| OtherGandA | 31.76M | 39.06M | 22.41M | 19.55M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 1.00M |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 1.00M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 87.13M | 64.58M | 53.72M | 25.27M |
| ShareIssued | 87.13M | 64.58M | 53.72M | 25.27M |
| TotalDebt | 1.35M | 603.00K | 1.21M | 0.00 |
| TangibleBookValue | 345.87M | 255.37M | 276.94M | 160.30M |
| InvestedCapital | 345.87M | 255.37M | 276.94M | 160.30M |
| WorkingCapital | 346.46M | 255.49M | 276.72M | 160.11M |
| NetTangibleAssets | 345.87M | 255.37M | 276.94M | 160.30M |
| CapitalLeaseObligations | 1.35M | 603.00K | 1.21M | 0.00 |
| CommonStockEquity | 345.87M | 255.37M | 276.94M | 160.30M |
| TotalCapitalization | 345.87M | 255.37M | 276.94M | 160.30M |
| TotalEquityGrossMinorityInterest | 345.87M | 255.37M | 276.94M | 160.30M |
| StockholdersEquity | 345.87M | 255.37M | 276.94M | 160.30M |
| GainsLossesNotAffectingRetainedEarnings | -279.00K | -19.00K | -822.00K | -338.00K |
| OtherEquityAdjustments | -279.00K | -19.00K | -822.00K | -338.00K |
| RetainedEarnings | -421.48M | -332.63M | -242.42M | -182.07M |
| AdditionalPaidInCapital | 767.62M | 588.01M | 520.18M | 342.71M |
| CapitalStock | 9.00K | 6.00K | 5.00K | 3.00K |
| CommonStock | 9.00K | 6.00K | 5.00K | 3.00K |
| PreferredStock | 0.00 | |||
| TotalLiabilitiesNetMinorityInterest | 18.06M | 13.15M | 10.08M | 7.77M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 2.41M | 1.21M | 1.61M | 947.00K |
| TradeandOtherPayablesNonCurrent | 1.49M | 1.21M | 1.07M | 787.00K |
| NonCurrentDeferredLiabilities | 0.00 | 160.00K | ||
| LongTermDebtAndCapitalLeaseObligation | 919.00K | 0.00 | 544.00K | 0.00 |
| LongTermCapitalLeaseObligation | 919.00K | 0.00 | 544.00K | 0.00 |
| CurrentLiabilities | 15.65M | 11.94M | 8.47M | 6.82M |
| OtherCurrentLiabilities | 455.00K | 278.00K | 185.00K | 358.00K |
| CurrentDeferredLiabilities | 0.00 | |||
| CurrentDeferredRevenue | 0.00 | |||
| CurrentDebtAndCapitalLeaseObligation | 428.00K | 603.00K | 661.00K | |
| CurrentCapitalLeaseObligation | 428.00K | 603.00K | 661.00K | 0.00 |
| PensionandOtherPostRetirementBenefitPlansCurrent | 7.91M | 5.68M | 3.84M | 2.40M |
| PayablesAndAccruedExpenses | 6.86M | 5.38M | 3.78M | 4.06M |
| CurrentAccruedExpenses | 4.71M | 2.87M | 2.13M | 1.93M |
| Payables | 2.15M | 2.52M | 1.65M | 2.13M |
| AccountsPayable | 2.15M | 2.52M | 1.65M | 2.13M |
| TotalAssets | 363.93M | 268.52M | 287.03M | 168.07M |
| TotalNonCurrentAssets | 1.82M | 1.08M | 1.84M | 1.14M |
| OtherNonCurrentAssets | 350.00K | 56.00K | 37.00K | 94.00K |
| NetPPE | 1.47M | 1.03M | 1.80M | 1.05M |
| AccumulatedDepreciation | -1.89M | -1.61M | -1.40M | -1.19M |
| GrossPPE | 3.36M | 2.64M | 3.21M | 2.23M |
| Leases | 750.00K | 734.00K | 758.00K | 928.00K |
| OtherProperties | 747.00K | 770.00K | 758.00K | 718.00K |
| MachineryFurnitureEquipment | 617.00K | 611.00K | 643.00K | 585.00K |
| BuildingsAndImprovements | 1.25M | 523.00K | 1.05M | |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 362.11M | 267.43M | 285.19M | 166.93M |
| OtherCurrentAssets | 3.94M | 3.99M | 2.07M | 948.00K |
| CurrentDeferredAssets | 0.00 | |||
| PrepaidAssets | 948.00K | |||
| Receivables | 0.00 | |||
| NotesReceivable | 0.00 | |||
| CashCashEquivalentsAndShortTermInvestments | 358.16M | 263.44M | 283.11M | 165.98M |
| OtherShortTermInvestments | 196.72M | 183.51M | 139.88M | 118.28M |
| CashAndCashEquivalents | 161.44M | 79.93M | 143.24M | 47.70M |
| CashEquivalents | 147.57M | 33.79M | 23.03M | 33.24M |
| CashFinancial | 13.87M | 46.14M | 120.21M | 14.46M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -70.06M | -67.44M | -49.38M | -42.17M |
| RepaymentOfDebt | 0.00 | -12.88M | ||
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 162.31M | 41.61M | 167.25M | 136.36M |
| CapitalExpenditure | -42.00K | -52.00K | -275.00K | -340.00K |
| IncomeTaxPaidSupplementalData | 60.00K | 28.00K | 3.00K | 238.00K |
| EndCashPosition | 161.44M | 79.93M | 143.24M | 47.70M |
| BeginningCashPosition | 79.93M | 143.24M | 47.70M | 74.85M |
| EffectOfExchangeRateChanges | -56.00K | 117.00K | -178.00K | -25.00K |
| ChangesInCash | 81.57M | -63.43M | 95.71M | -27.13M |
| FinancingCashFlow | 164.00M | 41.95M | 167.09M | 134.39M |
| CashFlowFromContinuingFinancingActivities | 164.00M | 41.95M | 167.09M | 134.39M |
| NetOtherFinancingCharges | -388.00K | -344.00K | -401.00K | 10.00M |
| ProceedsFromStockOptionExercised | 2.07M | 684.00K | 243.00K | 914.00K |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 162.31M | 41.61M | 167.25M | 136.36M |
| CommonStockIssuance | 162.31M | 41.61M | 167.25M | 136.36M |
| NetIssuancePaymentsOfDebt | 0.00 | -12.88M | ||
| NetLongTermDebtIssuance | 0.00 | -12.88M | ||
| LongTermDebtPayments | 0.00 | -12.88M | ||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -12.41M | -37.99M | -22.27M | -119.70M |
| CashFlowFromContinuingInvestingActivities | -12.41M | -37.99M | -22.27M | -119.70M |
| NetInvestmentPurchaseAndSale | -12.37M | -37.94M | -22.00M | -119.36M |
| SaleOfInvestment | 157.57M | 237.85M | 117.73M | 46.94M |
| PurchaseOfInvestment | -169.94M | -275.78M | -139.73M | -166.30M |
| NetPPEPurchaseAndSale | -42.00K | -52.00K | -275.00K | -340.00K |
| PurchaseOfPPE | -42.00K | -52.00K | -275.00K | -340.00K |
| OperatingCashFlow | -70.02M | -67.39M | -49.11M | -41.83M |
| CashFlowFromContinuingOperatingActivities | -70.02M | -67.39M | -49.11M | -41.83M |
| ChangeInWorkingCapital | 4.38M | 1.48M | -1.04M | -1.43M |
| ChangeInOtherWorkingCapital | -610.00K | -60.00K | ||
| ChangeInOtherCurrentLiabilities | -555.00K | -666.00K | -610.00K | 0.00 |
| ChangeInOtherCurrentAssets | 0.00 | 37.00K | ||
| ChangeInPayablesAndAccruedExpense | 4.89M | 4.06M | 694.00K | -1.64M |
| ChangeInAccruedExpense | 5.26M | 2.91M | 1.42M | -3.37M |
| ChangeInInterestPayable | 1.01M | 184.00K | ||
| ChangeInPayable | -367.00K | 1.15M | -722.00K | 1.73M |
| ChangeInAccountPayable | -367.00K | 1.15M | -722.00K | 1.73M |
| ChangeInPrepaidAssets | 47.00K | -1.92M | -1.12M | 238.00K |
| StockBasedCompensation | 15.63M | 25.54M | 10.77M | 8.15M |
| AmortizationOfSecurities | -2.09M | -5.21M | 81.00K | 879.00K |
| DeferredTax | 23.00K | 141.00K | 392.00K | 219.00K |
| DeferredIncomeTax | 23.00K | 141.00K | 392.00K | 219.00K |
| DepreciationAmortizationDepletion | 896.00K | 881.00K | 1.03M | 512.00K |
| DepreciationAndAmortization | 896.00K | 881.00K | 1.03M | 512.00K |
| Depreciation | 896.00K | 881.00K | 1.03M | 512.00K |
| NetIncomeFromContinuingOperations | -88.85M | -90.21M | -60.34M | -50.16M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for TERN
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|